CRISPR Therapeutics Vertex Pharmaceuticals: Better Buy in 2026
Investors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
Determining which travel rewards credit card is best can enhance your travel experiences. Explore your options for the best fit.
23,300 articlesInvestors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
The AI boom relies on more than chips. It hinges on the invisible backbone—equipment that enables chipmakers to scale...
Cloudflare surged about 9% in midday trading after a Scotiabank upgrade. The move comes as AI cloud peers like Oracle...
Investors are eyeing yuanbao (yb) 2026 earnings as the company pivots toward new revenue streams. This guide breaks d...
When an energy storage company reports stronger results, the market often reacts with a sharp stock move. This guide ...
Jamie Dimon drops a bold note on AI’s real impact at JPMorgan: it’s already trimming headcount in some units, but pro...
A veteran wealth manager bets international exposure through a broad non-U.S. ETF to diversify risk and tap growth ou...
Stepan (SCL) investors are focused on 2025 earnings drivers, margins, and cash flow. This guide breaks down the key c...
AI data centers are expanding fast, backed by major cloud players. This article dives into why hyperscalers plan spen...
Cumberland's 2025 earnings signal steady growth and improving margins, with a diversified product mix and a promising...
NVIDIA is backing two optics-focused AI companies with billions of dollars, a move that helped them earn spots in the...
A fresh stake of roughly $4.5 million by a value-focused firm in Workiva raises questions about what comes next for W...